NSW Ends Automatic Licence Loss for Medical Cannabis Drivers

New South Wales will introduce legislation this month to replace automatic licence penalties for medicinal cannabis patients with a registration-and-threshold scheme — the first time Australia’s most populous state has moved to formally separate a prescribed patient’s legal status from its roadside drug-detection framework.

The Minns Labor Government announced the reform on June 4, 2026, with the bill to be introduced in the final sitting week of June. The change addresses a structural problem that has followed Australia’s medicinal cannabis expansion: patients legally prescribed THC-containing medicines have faced the same zero-tolerance roadside regime as recreational users, a positive drug swab triggering automatic penalties regardless of whether the driver showed any sign of impairment.

NSW holds an estimated 300,000 medicinal cannabis patients — roughly one in three of Australia’s approximately one million total — and the number of cannabis medicines dispensed monthly in the state has nearly doubled over the past year.

How the registration scheme works

Under the proposed system, eligible drivers must enrol as registered medicinal cannabis users with Transport for NSW, provide proof of a valid prescription, and complete an online education module on cannabis and road safety. Registration is the gateway to the scheme; it does not suspend roadside testing.

Oral-fluid swabs at the roadside continue unchanged. A positive result still triggers an immediate 24-hour driving ban while the sample goes for laboratory analysis. What changes is what happens once those results return.

If the laboratory finds THC below 50 nanograms per milliliter, a registered patient faces no charge and no further action. Above that threshold, the government applies a three-strike structure within any two-year window: a first or second detection draws a warning letter, giving the patient time to adjust dosing or timing relative to driving. A third detection above the threshold within the same period results in a fine of AU$704 and a minimum three-month licence suspension.

The scheme is explicitly narrow. Learner and probationary licence holders are excluded, as are all commercial drivers — a distinction reflecting the higher safety obligations those licences carry. Any driver found to be actually impaired, or who returns a result showing alcohol or other drugs alongside THC, faces the existing drug-driving offence in full. Post-crash blood and urine testing following serious accidents continues as before.

The reform implements a recommendation from the state’s 2024 Drug Summit, which called for a legislated medical defence for patients driving unimpaired. A one-year review is built into the new system.

Reform progress across Australia

NSW’s move arrives against a national picture that remains uneven.

Tasmania already gives courts discretion over licence outcomes for patients who test positive to THC while on a valid prescription. Victoria has, since March 2025, given magistrates discretion to decline licence cancellation where a patient tests positive but was not impaired. Western Australia has convened its own expert working group on the question — but according to industry coverage, the working group’s report was delivered to the relevant state minister several months ago without a public government response. A Legislative Council member from WA’s Legalise Cannabis Party told industry media he had repeatedly put parliamentary questions to the Cook government on the report’s status and been told each time that the government is continuing to consider the matter.

A private member’s bill introduced in the NSW Legislative Assembly in November 2025 — which would have amended road transport law to limit the drug-presence offence for medicinal cannabis users — was withdrawn in May 2026 ahead of the government’s own legislation. The Minns Government’s version differs from what the earlier bill proposed: rather than a broad exclusion from the drug-presence offence, it creates a structured registration-and-threshold model with defined escalation.

The 50 ng/mL laboratory threshold is the substantive policy innovation. As MyCannabis has previously examined, the relationship between detectable THC and actual driving impairment is genuinely complex — THC remains detectable in oral fluid well after any psychoactive effect has passed, and the gap between presence and impairment is the core scientific (CORZ ) dispute underlying driving laws in every jurisdiction working through medicinal cannabis reform. By setting a laboratory figure, NSW is attempting to bring enforcement closer to that science, rather than maintaining the zero-tolerance model that treats any detectable level as an offence regardless of impairment. Whether 50 ng/mL proves the right number is precisely what the one-year review is designed to test.

What comes next

The legislation is expected to be introduced before the NSW Parliament rises in late June 2026. If it passes, Transport for NSW will need to stand up the registration infrastructure — prescription verification, education module delivery, and database integration with roadside testing — before the provisions can take effect. The design of that system will determine whether the scheme operates as drafted or creates enforcement gaps at the operational level.

For businesses tracking Australian market access conditions, the one-year review is the mechanism that matters. Its scope and the data it draws on will shape whether NSW’s threshold-and-registration model is preserved, tightened, or broadened — and whether states that have moved more slowly use it as a template for their own reforms.